Enliven Therapeutics, Inc. (NASDAQ:ELVN) Given Consensus Recommendation of “Moderate Buy” by Analysts

Enliven Therapeutics, Inc. (NASDAQ:ELVN) has been given a consensus rating of “Moderate Buy” by the five research firms that are covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell rating and four have issued a buy rating on the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $41.00.

ELVN has been the subject of several research reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Enliven Therapeutics in a research report on Wednesday, January 21st. Wall Street Zen lowered shares of Enliven Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, February 28th.

Enliven Therapeutics Trading Up 1.5%

ELVN opened at $27.79 on Wednesday. The company has a market capitalization of $1.66 billion, a price-to-earnings ratio of -14.94 and a beta of 0.33. Enliven Therapeutics has a 12-month low of $13.30 and a 12-month high of $30.98. The business’s fifty day simple moving average is $27.20 and its 200-day simple moving average is $22.31.

Enliven Therapeutics (NASDAQ:ELVN) last released its quarterly earnings data on Tuesday, March 3rd. The company reported ($0.48) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.06). On average, equities research analysts predict that Enliven Therapeutics will post -1.95 EPS for the current year.

Insider Buying and Selling

In related news, insider Joseph P. Lyssikatos sold 5,000 shares of the company’s stock in a transaction on Friday, February 6th. The stock was sold at an average price of $29.04, for a total transaction of $145,200.00. Following the completion of the sale, the insider directly owned 740,188 shares in the company, valued at $21,495,059.52. This represents a 0.67% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, Director Richard A. Heyman sold 1,230 shares of the company’s stock in a transaction on Tuesday, February 17th. The stock was sold at an average price of $26.18, for a total value of $32,201.40. Following the sale, the director owned 22,647 shares of the company’s stock, valued at $592,898.46. This trade represents a 5.15% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 237,180 shares of company stock worth $6,301,233 over the last quarter. Insiders own 25.90% of the company’s stock.

Hedge Funds Weigh In On Enliven Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Vestal Point Capital LP raised its holdings in Enliven Therapeutics by 230.2% in the fourth quarter. Vestal Point Capital LP now owns 3,830,000 shares of the company’s stock worth $58,982,000 after purchasing an additional 2,670,000 shares in the last quarter. TCG Crossover Management LLC bought a new stake in shares of Enliven Therapeutics in the 2nd quarter valued at about $9,990,000. Duquesne Family Office LLC boosted its holdings in shares of Enliven Therapeutics by 104.6% in the 3rd quarter. Duquesne Family Office LLC now owns 947,405 shares of the company’s stock valued at $19,393,000 after buying an additional 484,405 shares in the last quarter. Spruce Street Capital LP purchased a new position in shares of Enliven Therapeutics in the 4th quarter worth approximately $6,870,000. Finally, Polar Capital Holdings Plc grew its position in shares of Enliven Therapeutics by 13.5% in the 4th quarter. Polar Capital Holdings Plc now owns 3,513,680 shares of the company’s stock worth $54,111,000 after buying an additional 418,673 shares during the last quarter. Hedge funds and other institutional investors own 95.08% of the company’s stock.

Enliven Therapeutics Company Profile

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.